about
Ratios of involved nodes in early breast cancer.Proteomic identification of heat shock protein 70 as a candidate target for enhancing apoptosis induced by farnesyl transferase inhibitor.Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer.Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study.Optimal modeling for phase I design of a two drug combination-results of a phase I study of cisplatin with 9-nitrocamptothecin.Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors.Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix.The role of macrophages in antitumor defense of patients with ovarian cancer.Present knowledge of gynecologic sarcoma management.Negotiating for success: navigating the contracting process for an exemplary research program.GPR30 predicts poor survival for ovarian cancerDR6 as a diagnostic and predictive biomarker in adult sarcoma.Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.Intracavitary therapies for mesothelioma.Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer.Malignant adnexal masses in pregnancy.Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005.Molecular and epidemiological characteristics of inflammatory breast cancer in Algerian patients.A phase I study of the combination of temsirolimus with irinotecan for metastatic sarcomaRate of thromboembolic events in mesothelioma.Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors.Novel chemotherapy approaches for cervical cancer.Randomized phase II study of loratadine for the prevention of bone pain caused by pegfilgrastim.Systemic management strategies for metastatic soft tissue sarcoma.Gynaecological cancers in pregnancy.Topoisomerase 1 inhibitors and cancer therapy.Prognosis of hepatoid yolk sac tumor in women: what's up, Doc?Incidence and survival rates for female malignant germ cell tumors.Breast cancer screening in patients with cancers other than breast.Frequent overexpression of STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer.Cyclin E deregulation alters the biologic properties of ovarian cancer cells.Effects of interleukin-1 alpha on ovarian carcinoma in patients with recurrent disease.Subacute encephalopathic toxicity of cisplatin.Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic colorectal cancer.Paraneoplastic syndromes of gynecologic neoplasms.Epigenetic landscape of acute myelogenous leukemia--moving toward personalized medicineA phase I study of flavopiridol in combination with gemcitabine and irinotecan in patients with metastatic cancer.Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies.Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer.Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer.
P50
Q24796013-07864415-D7FC-41F8-AC68-A02DE6F12BB2Q31027123-49DC28FE-D8DF-48A2-8FBF-B1EF8D3CCA38Q33331589-2B301BEB-2538-4D05-A01E-638B0832423EQ33343039-368B1F98-D620-49AE-8A41-AA6FA32868C7Q33380203-DC2ED771-DB08-47A0-AF9F-5AC0A54D829FQ33394175-99F60FC8-3814-4B65-8405-CA22A8D7FD14Q33498584-D1D8D2CE-A5A2-4C2C-ADC6-0BD64CD83134Q33541937-3FF1FF15-988D-4ACF-8C4D-AA49967C7CEBQ33541948-75C27888-94E1-4CF2-A7F0-F11AD333A7B1Q33715078-2A1A79D7-2DCA-40EB-AC9F-CA84F1014C5DQ34066297-18104530-FB2E-44DB-BA5F-8E3B91F2C782Q34261836-E90457F5-28DF-4E1E-AB61-F19E77A88534Q34616628-90AA9FD0-B6B4-492A-A194-45B83AF188A1Q34677967-064AF746-3E8C-4574-B0C4-ABB4D6D59EF3Q35653739-518BE41E-AF2B-46AF-9E0C-788BD0537687Q36323701-7CA5A644-9B33-4BB4-9FD2-FCE0BD285FA4Q36346636-771B140A-A9EC-4EA9-B4A6-D968BDB9AD58Q36587844-ABC40E5F-EE00-4AB5-9623-D5287C304BC5Q37061813-0C57F697-2126-41EC-9A08-0B64386B91C5Q37091198-889D9AF1-EC47-45C5-A862-25932A21469DQ37372615-9C9B8AAC-1B24-45FD-ABE3-F38D55C30C7FQ37487981-B5E37B1B-1086-4D2B-A24E-B08C27C5EAECQ37606891-798CE87E-B8B0-447F-9E15-C2B15EC12D8BQ37950516-E99244F6-8E1F-473E-A68A-29CEE779AD4DQ37983216-413B2EF0-E72E-41D0-B825-9846292E9DD6Q38004214-41AD1D32-4AB1-482D-8CC2-D990EB73E1E6Q38181769-491319FA-8827-45DC-8B2D-D37EC5FDD683Q38468558-D87BEF21-786F-4D29-834D-477D8F0BCFF4Q38925847-3EB8B9AE-D220-4493-B895-A72E62F7EAD9Q40433380-E6203A1B-68B8-480F-80B8-35FAE5A232C6Q40580984-9669EEC6-7A36-4233-9C5F-1B7DCA7B497DQ40665294-42A85126-4D18-44AB-A213-94D519F11E36Q41041893-E39148A5-172B-422C-9AF2-63DC3CBF9AE3Q41159101-880B3864-DA7D-424A-AE56-E6CF7F7580E0Q41374455-4B475AD0-A152-4E5E-8A34-78E81E2FBEEBQ41861253-32EE31FE-42C1-49FC-8E78-1F64ADFE91B0Q43249968-5289254E-E05D-4DFF-8B31-E74092BC5811Q43542851-EC05A838-8D9D-4E3D-AA28-91C609490A4FQ44327930-C1DA8CB0-76B8-4DD8-9558-FC2CD74D01D9Q44587948-1ADFCEDC-B346-4B62-83C5-1BE54C1D43AE
P50
description
American oncologist
@en
name
Claire F. Verschraegen
@en
Claire F. Verschraegen
@fr
Claire Verschraegen
@ast
Claire Verschraegen
@es
Claire Verschraegen
@nl
type
label
Claire F. Verschraegen
@en
Claire F. Verschraegen
@fr
Claire Verschraegen
@ast
Claire Verschraegen
@es
Claire Verschraegen
@nl
altLabel
Claire Verschraegen
@en
Claire Verschraegen
@fr
prefLabel
Claire F. Verschraegen
@en
Claire F. Verschraegen
@fr
Claire Verschraegen
@ast
Claire Verschraegen
@es
Claire Verschraegen
@nl
P106
P1153
7006943691
P21
P31
P496
0000-0001-6544-3089